Daniél Vega Møller, n/a

Novo Nordisk A/S,
Søborg, Denmark, Denmark

Poster(s):

• (P173) ONCE-WEEKLY SEMAGLUTIDE IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION, OBESITY AND TYPE 2 DIABETES: MAIN RESULTS FROM THE STEP-HFPEF DM TRIAL
  Friday, October 25, 2024

  1:30 PM – 2:00 PM PT